Indication
Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.
Loading your page…
Loading your page…
Parkinson Disease
Marketing Authorisation Holder: Teva B.V.
EMA Authorisation: 21/02/2005
INN: rasagiline
AI Drug & Interaction Analysis
Free account required
Ask Osler about Azilect: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.